INTERLEUKIN 13 (IL-13) ACTS AS A PROFIBROTIC CYTOKINE FOR RECRUITMENT OF MYOFIBROBLASTS IN ORAL SUBMUCOUS FIBROSIS

被引:1
|
作者
Reddy, Mamatha G. S. [1 ]
Sarode, Sachin C. [1 ]
Desai, Rajiv S. [2 ]
机构
[1] Dr DY Patil Dent Coll & Hosp, DY Patil Vidyapeeths, Pune 411018, Maharashtra, India
[2] Nair Dent Hosp & Coll, Mumbai 400008, Maharashtra, India
关键词
Interleukin; 13; myofibroblasts; oral submucous fibrosis; pathogenesis; transfouning growth factor-beta; LUNG FIBROBLASTS; TISSUE FIBROSIS; EXPRESSION; PATHOGENESIS; MECHANISMS; BETA;
D O I
10.5958/0974-4517.2019.00028.4
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Oral submucous fibrosis (OSF) is a chronic inflammatory condition due to areca nut (Areca catechu) chewing which induces fibrosis leading to the difficulty in mouth opening. Various profibrotic cytokines and chemokines have been found involved in fibrosis. The present study was aimed to find the role of interleukin 13 (IL-13) in recruiting the myofibroblasts and as a causative factor for fibrosis in OSF. Twenty-five sections of OSF tissue and ten sections of normal mucosa were stained with IL -13, TGF-beta 1 and alpha-SMA antibodies using immunohistochemical method. Immunostaining was done to assess staining intensity and percentage of positive cells. The results were analyzed by SPSS software. The expression of all three markers IL-13, TGF-beta 1 and alpha-SMA showed significant difference between control and OSF (p < 0.001), control and early OSF (p < 0.001) control and advanced OSF (p < 0.001). No statistical difference was found between early OSF and advanced OSF. Significant expression of IL-13 and its correlation with TGF-beta and alpha-SMA suggests its role in pathogenesis of OSF.
引用
收藏
页码:221 / 227
页数:7
相关论文
共 50 条
  • [41] Interleukin-13 (IL-13) in autoimmune rheumatic diseases: relationship with autoantibody profile
    Rinaldi, T.
    Spadaro, A.
    Riccieri, V.
    Taccari, E.
    Valesini, G.
    ARTHRITIS RESEARCH & THERAPY, 2001, 3 (Suppl 2)
  • [42] The Regulation Of Cxcr3 And Il-13rα2 By Il-13 In Pulmonary Fibrosis
    Worrell, J.
    Walsh, S.
    Fabre, A.
    Kane, R.
    Keane, M. P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [43] Lysophosphatidic acid induces interleukin-13 (IL-13) receptor α2 expression and inhibits IL-13 signaling in primary human bronchial epithelial cells
    Zhao, Yutong
    He, Donghong
    Zhao, Jing
    Wang, Lixin
    Leff, Alan R.
    Spannhake, Ernst Wm.
    Georas, Steve
    Natarajan, Viswanathan
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (14) : 10172 - 10179
  • [44] Select Effects of IL-13 in Driving Tissue Repair and Fibrosis
    Alegre, Maria-Luisa
    AMERICAN JOURNAL OF TRANSPLANTATION, 2016, 16 (10) : 2771 - 2771
  • [45] Role of IL-4/IL-13 in the Development of Skin Fibrosis investigated
    Lichert, Frank
    AKTUELLE DERMATOLOGIE, 2019, 45 (12) : 576 - 576
  • [46] Distinct roles for IL-13 and IL-17 in chronic inflammation and fibrosis
    Wynn, Thomas
    Ramalingam, Thirumalai
    Madala, Satish
    Thompson, Robert
    Mentink, Margaret
    Barron, Luke
    Cheever, Allen
    Wilson, Mark
    JOURNAL OF IMMUNOLOGY, 2010, 184
  • [47] The Interleukin 13 (IL-13) Pathway in Human Macrophages Is Modulated by MicroRNA-155 via Direct Targeting of Interleukin 13 Receptor α1 (IL13Rα1)
    Martinez-Nunez, Rocio T.
    Louafi, Fethi
    Sanchez-Elsner, Tilman
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (03) : 1786 - 1794
  • [48] The Regulation Of Interleukin-13 Receptor Subunits In Response To Mechanical Wounding And Il-13 Exposure
    Yang, S. -Y.
    Singhera, G. K.
    Dorscheid, D. R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [49] The IL-4/IL-13 signaling axis promotes prostatic fibrosis
    D'Arcy, Quentin
    Gharaee-Kermani, Mehrnaz
    Zhilin-Roth, Alisa
    Macoska, Jill A.
    PLOS ONE, 2022, 17 (10):
  • [50] Specifically targeted killing of interleukin-13 (IL-13) receptor-expressing breast cancer by IL-13 fusion cytotoxin in animal model of human disease
    Kawakami, K
    Kawakami, M
    Puri, RK
    MOLECULAR CANCER THERAPEUTICS, 2004, 3 (02) : 137 - 147